Ken Griffin Enlivex Therapeutics Ltd. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 200 shares of ENLV stock, worth $272. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 7,600
97.37%
Holding current value
$272
Previous $20,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ENLV
# of Institutions
22Shares Held
341KCall Options Held
22.8KPut Options Held
29.1K-
Morgan Stanley New York, NY72.1KShares$98,0830.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny69.9KShares$95,0490.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA67.9KShares$92,4020.0% of portfolio
-
Simplex Trading, LLC18.3KShares$24,8340.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$20,4000.09% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $25M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...